MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: strong cash position and reduced expenses are positives, but declining gross margins and lack of specific guidance for SPL milestones are concerns. The Q&A highlights cautious optimism regarding future growth and partnerships, but uncertainties about revenue contributions persist. The company's strategic focus on expanding product offerings and technological capabilities aligns with positive market trends. However, the absence of immediate catalysts and management's reluctance to provide detailed guidance suggest a neutral stock price movement over the next two weeks.
Key Financial Performance
Total Revenue $9.7 million in Q1 2026, a 7% decrease year-over-year from $10.4 million in Q1 2025. The decline was driven by a decrease in core revenue, partially offset by growth in SPL program-related revenue.
Core Revenue $6.2 million in Q1 2026, a 25% decrease year-over-year from $8.2 million in Q1 2025. The decline was attributed to inventory management at the largest SPL customer and discontinued SPL programs.
SPL Program-Related Revenue $3.4 million in Q1 2026, an increase from $2.1 million in Q1 2025. This growth included $3 million from milestones tied to a clinical customer dosing patients in a registrational study and $0.4 million in royalty revenue.
Gross Margin 84% in Q1 2026, a slight decrease from 86% in Q1 2025. Non-GAAP adjusted gross margin was 78% in Q1 2026 compared to 83% in Q1 2025, impacted by inventory provisions and SPL program-related revenue.
Operating Expenses $14.3 million in Q1 2026, a decrease of approximately $7 million from $21.2 million in Q1 2025. The reduction reflects restructuring and cost efficiency actions taken in 2025.
Cash, Cash Equivalents, and Investments $147.7 million at the end of Q1 2026, with no debt. This strong balance sheet provides flexibility for strategic investments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ExPERT DTx: The commercial launch of ExPERT DTx is progressing well with early traction in discovery and early optimization workflows across ex-vivo and in-vivo CGT as well as protein screening for biologics development. Adoption is expected to increase in the second half of 2026 and into next year.
SeQure: Steady progress is being made with new assay service agreements added in Q1 2026. Customer engagement spans ex-vivo and in-vivo developers, with several programs approaching IND-enabling stages. The FDA's draft guidance on genome editing safety assessment is seen as a structural positive for SeQure.
Casgevy: Vertex reported $43 million in Casgevy revenue for Q1 2026. Over 500 patients have initiated treatment globally, with hundreds completing cell collection. Regulatory progress includes a supplemental BLA submission for younger patients, highlighting the therapy's multibillion-dollar potential.
Revenue Performance: Total revenue for Q1 2026 was $9.7 million, a 7% decrease from Q1 2025. Core revenue declined by 25% to $6.2 million, while SPL program-related revenue grew to $3.4 million.
Cost Efficiency: Operating expenses decreased by $7 million year-over-year due to 2025 restructuring and cost efficiency actions. The company does not expect significant growth in operating expenses moving forward.
Share Repurchase Program: The Board authorized a $10 million share repurchase program, reflecting confidence in the company's long-term value and financial strength.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Core Revenue Decline: Core revenue decreased by 25% year-over-year, driven by inventory management at the largest SPL customer and discontinued SPL programs. This decline reflects challenges in maintaining consistent revenue streams from core operations.
SPL Program Turnover: Elevated turnover in SPL programs, including discontinued partnerships with Catamaran Bio and Walking Fish Therapeutics, highlights risks in maintaining long-term collaborations and revenue stability.
Market Challenges in Cell and Gene Therapy: The cell and gene therapy ecosystem remains challenging for earlier-stage clinical programs due to a difficult funding environment, potentially impacting future growth and partnerships.
Regulatory and Clinical Risks: While there are multiple clinical programs in the pipeline, each carries inherent clinical and regulatory risks, which could impact the realization of milestones and royalties.
Cost Structure Adjustments: Although cost efficiency actions have been implemented, the company faces risks in maintaining reduced operating expenses while achieving revenue growth.
Revenue Concentration: 44% of core revenue was generated from SPL partners, down from 57% in the prior year, indicating dependency on a limited number of partners and potential vulnerability to partner-specific issues.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Core Revenue Growth: MaxCyte expects core revenue growth in the second half of 2026, driven by a qualified instrument funnel, easier comparisons, and contributions from the new DTx product.
SPL Milestones and Royalties: The company anticipates $5 million in SPL milestones and royalties for 2026, with $3 million already recognized in Q1. The remaining $2 million is expected from commercial royalties.
Future SPL Programs: MaxCyte supports 30 clinical and preclinical programs, with 5 clinical programs potentially launching commercially in 2027 and 2028. Four of these programs are expected to enter registrational trials within the next 18 months.
ExPERT DTx Product Adoption: The commercial launch of the ExPERT DTx product is progressing well, with increased adoption expected in the second half of 2026 and into 2027.
SeQure Assay Services: Steady progress is being made in building the commercial engine for SeQure assay services, with new agreements signed in Q1 2026. The company expects these services to become an industry standard for off-target risk assessment in gene editing.
Operating Expenses: Operating expenses are not expected to grow meaningfully in 2026, following cost efficiency actions taken in 2025.
Cash Position: MaxCyte expects to end 2026 with at least $136 million in cash, cash equivalents, and investments, excluding capital deployed for the share repurchase program.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: The Board of Directors authorized a $10 million share repurchase program. The decision reflects confidence in MaxCyte's long-term value, strategic investments, and business prospects. The company plans to execute the majority of the repurchase program before the year-end 2026. Shares may be repurchased through open market purchases, privately negotiated transactions, block trades, or other means, subject to applicable securities laws.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:On the SPL revenue guidance, why are no milestones being guided for the remainder of the year despite active programs?
A:The agreements are structured based on dosing timing in pivotal trials, not on the initiation of pivotal trials. While another milestone is possible, it is more likely to occur in the first part of next year depending on the dosing regimen.
Q:What is the expected cadence of license fees during the year?
A:The company expects to sign at least 3 SPL partners this year, though none have been signed in the first half. Negotiations with potential partners often take 18-24 months, and the company remains confident in achieving its target.
Q:What is the expected contribution of SeQure DX to revenue growth over the next 12-24 months?
A:SeQure DX generated $0.6 million in revenue in Q1, showing 11% sequential growth and 3x growth year-over-year. The company expects substantial year-over-year growth as the commercial pipeline continues to build.
Q:What is the expected cadence of the share buyback program?
A:The company plans to execute the majority of the share repurchase program by year-end, using a mix of open market purchases and systematic approaches.
Q:What is the industry backdrop and sales funnel outlook for the company?
A:The company sees stability in later-stage clinical programs, with 11 SPL partners and 12 clinical programs progressing. Financing remains challenging for early-stage cell therapy, but later-stage programs are attracting investor interest.
Q:What are the CFO's priorities for forecasting and financial analytics?
A:The CFO aims to evolve financial analytics and forecasting, support commercial and product development initiatives, and maintain a disciplined cost structure.
Q:What is the expected growth trajectory for SeQure DX for the remainder of the year?
A:The company expects significant year-over-year growth but is cautious about predicting quarterly cadence. SeQure DX is a services business, and revenue timing differs from the MaxCyte electroporation business.
Q:What is the outlook for gross margins for the year?
A:Gross margins are expected to trend in the mid-70s percentage range for the rest of the year, despite challenges in Q1.
Q:What is the progress and outlook for the DTx system launch?
A:The DTx system is meeting expectations, with sales expected to increase in the second half of the year. The system is gaining traction in academic accounts, protein screening for biologics, and big pharma.
Q:What is the state of the SPL portfolio and future growth prospects?
A:The SPL portfolio includes 11 partners with 12 clinical programs, many progressing to pivotal and registrational studies. The company remains confident in signing 3-5 new SPLs annually, with a focus on lead assets.
Q:What is the expected run rate for G&A expenses and overall OpEx for the year?
A:G&A expenses are expected to remain around $6 million per quarter, with overall OpEx projected at approximately $60 million for the year, down from $79-80 million last year.
Q:What is the expected revenue contribution from the DTx system in the second half of the year?
A:The DTx system's revenue contribution is included in the company's guidance, with meaningful growth expected in the second half of the year.
Q:What trends are observed in the SPL portfolio regarding modalities, cell types, and indications?
A:The SPL portfolio is evenly split between autologous and allogeneic programs, with a focus on T-cells. Allogeneic CAR-T programs and novel gene editing platforms are advancing, supported by FDA guidance.
Q:Review of Unclear Management Responses
A:Management avoided providing specific quarterly revenue projections for SeQure DX and the DTx system, citing the need to observe how the year progresses. Additionally, they did not disclose details about the confidential milestone payment received or specific SPL partner programs.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
DTx
GTx
MaxCyte Chief
Officer Parmeet
Parmeet today
SPL milestone
SPL partner
SPL program
SeQure
action PL
adoption
balance
cash
cell
collection infusion
core SPL
core milestone
cost efficiency
customer patient
decrease
development
editing
gene
instrument
investment
malignancy
milestone royalty
number
patient study
potential
product
repurchase program
share repurchase
stage
therapy
MXCT Transcript
MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call presents a mixed picture: strong cash position and reduced expenses are positives, but declining gross margins and lack of specific guidance for SPL milestones are concerns. The Q&A highlights cautious optimism regarding future growth and partnerships, but uncertainties about revenue contributions persist. The company's strategic focus on expanding product offerings and technological capabilities aligns with positive market trends. However, the absence of immediate catalysts and management's reluctance to provide detailed guidance suggest a neutral stock price movement over the next two weeks.
MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript
Positive3-25
The company's strong revenue growth, improved gross margin, and reduced net loss indicate positive financial performance. The optimistic revenue expectations and margin projections for 2026 further enhance the outlook. Although operational updates and risks were not discussed, the focus on product expansion and market recovery in biotech are promising. The absence of shareholder return details is a minor concern. Overall, the positive financial metrics and strategic initiatives suggest a likely positive stock price movement in the near term.
MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript
Unknown11-12
The earnings call reflects a mixed outlook. Financial performance shows stable gross margins but a decline in non-GAAP adjusted margins. The Q&A highlights positive developments in SeQure's ramp-up and SPL pipeline, but there's a cautious approach due to challenging biotech funding and M&A environment. The guidance for 2025 is weak, but there's optimism for 2026 growth. The lack of guidance on CASGEVY and revenue shifts raises concerns. Overall, the sentiment is neutral due to balanced positive and negative factors without a strong catalyst for significant stock movement.
MaxCyte, Inc. (MXCT) Q2 2025 Earnings Call Transcript
Unknown8-7
The earnings call summary indicates a mixed financial performance with a decline in total revenue, reduced gross margins, and increased operating expenses. The Q&A section reveals short-term revenue challenges due to inventory adjustments and macroeconomic headwinds, despite some positive signs in instrument sales and SPL programs. The lack of specific guidance and management's avoidance of details further contribute to uncertainty. Overall, these factors suggest a likely negative stock price movement over the next two weeks.
MXCT Slides
MXCT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
